Most Viewed Videos

Lisa A. Carey, MD, and Julie Gralow, MD: Top Breast Cancer Papers Presented at the 2016 ASCO Annual Meeting

Ursula A. Matulonis, MD, on Ovarian Cancer: Roundup of Studies on Olaparib, Cediranib, Mirvetuximab Soravtansine, Bevacizumab, and Pembrolizumab

Nathan Fowler, MD, and Sagar Lonial, MD, on Treating Follicular Lymphoma

Nicholas C. Turner, MD, PhD, Summarizes Results of the PALOMA3 Breast Cancer Study

Judith Paice, PhD, RN, on Neuropathic Pain

Nicholas J. van As, MD, on Prostate Cancer: Results From the PACE-B Trial Comparing Radiotherapy Techniques

Kenneth C. Anderson, MD, on Multiple Myeloma: Current Treatment Approaches and Future Directions

Bruce E. Johnson, MD, and Julie Vose, MD, MBA: A Conversation With ASCO’s 2017–2018 President

David I. Quinn, MBBS, PhD, on Urothelial Cancer: Results from KEYNOTE-045

Mark K. Ferguson, MD, on Mitigating Frailty and Sarcopenia to Improve Treatment Outcomes

Mark Talamonti, MD, on Pancreatic Cancer: Minimally Invasive Resection

Jonathan R. Strosberg, MD, on Neuroendocrine Tumors: Results of the NETTER-1 Trial

Julie Bryar Porter, MS, on Improving Care: One Center’s Experience

Jeff Dunn, AO, PhD, GAICD, on Community-Based Response to Cancer

Christian Carrie, MD, and Celestia S. Higano, MD, on Results of the GETUG-AFU 16 Trial on Prostate Cancer

Sumit K. Subudhi, MD, PhD, on Prostate Cancer: Results From the CheckMate 650 Trial on Nivolumab and Ipilimumab

Sumanta K. Pal, MD, and Toni K. Choueiri, MD, on Urothelial Carcinoma: Efficacy of an FGFR Inhibitor

Aug

Today In Oncology

Cancer Survivors Are Adhering to COVID-19–Related Preventive Behaviors, but Continuity of Care May Be Impacted

QoL With Open vs Minimally Invasive Radical Hysterectomy for Patients With Cervical Cancer

ESMO World GI: Third- or Later-Line Treatment With Infigratinib in Patients With Cholangiocarcinoma and FGR2 Fusions

Phase IB Trial of Atezolizumab With or Without Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma

Refinement of European LeukemiaNet Classification Recommendations for Younger Patients With AML

Christopher J. Recklitis, PhD, MPH, on Mental Health in Cancer Survivors

Gregory R. Pond, PhD, on Urothelial Cancer: Advance in Prognosis

Catherine C. Park, MD, on Novel Clinical Paradigms

Lisa A. Carey, MD, and Julie Gralow, MD: Top Breast Cancer Papers Presented at the 2016 ASCO Annual Meeting

Ursula A. Matulonis, MD, on Ovarian Cancer: Roundup of Studies on Olaparib, Cediranib, Mirvetuximab Soravtansine, Bevacizumab, and Pembrolizumab

Nathan Fowler, MD, and Sagar Lonial, MD, on Treating Follicular Lymphoma

Nicholas C. Turner, MD, PhD, Summarizes Results of the PALOMA3 Breast Cancer Study

Judith Paice, PhD, RN, on Neuropathic Pain

Nicholas J. van As, MD, on Prostate Cancer: Results From the PACE-B Trial Comparing Radiotherapy Techniques

Kenneth C. Anderson, MD, on Multiple Myeloma: Current Treatment Approaches and Future Directions

Bruce E. Johnson, MD, and Julie Vose, MD, MBA: A Conversation With ASCO’s 2017–2018 President

David I. Quinn, MBBS, PhD, on Urothelial Cancer: Results from KEYNOTE-045

Mark K. Ferguson, MD, on Mitigating Frailty and Sarcopenia to Improve Treatment Outcomes

Mark Talamonti, MD, on Pancreatic Cancer: Minimally Invasive Resection

Jonathan R. Strosberg, MD, on Neuroendocrine Tumors: Results of the NETTER-1 Trial

Julie Bryar Porter, MS, on Improving Care: One Center’s Experience

Jeff Dunn, AO, PhD, GAICD, on Community-Based Response to Cancer

Christian Carrie, MD, and Celestia S. Higano, MD, on Results of the GETUG-AFU 16 Trial on Prostate Cancer

Sumit K. Subudhi, MD, PhD, on Prostate Cancer: Results From the CheckMate 650 Trial on Nivolumab and Ipilimumab

Sumanta K. Pal, MD, and Toni K. Choueiri, MD, on Urothelial Carcinoma: Efficacy of an FGFR Inhibitor

Cancer Survivors Are Adhering to COVID-19–Related Preventive Behaviors, but Continuity of Care May Be Impacted

QoL With Open vs Minimally Invasive Radical Hysterectomy for Patients With Cervical Cancer

ESMO World GI: Third- or Later-Line Treatment With Infigratinib in Patients With Cholangiocarcinoma and FGR2 Fusions

Phase IB Trial of Atezolizumab With or Without Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma

Refinement of European LeukemiaNet Classification Recommendations for Younger Patients With AML